Antihemostatic and antithrombotic effects of XC386.
XC386 prolonged the tail bleeding time in the conscious mice. This effect was dose-dependent and persisted for at least six hours after the oral administration. XC386 was effective in preventing ADP-induced acute pulmonary thromboembolic death in mice at dose of 100 mg/kg. Aspirin and indomethacin had no effect on this model. XC386 also reduced the mortality rate in collagen- induced thromboembolic death at the same dose as aspirin and indomethacin (200 mg/kg). All three drugs caused no significant protection in endotoxin shock. XC386 was found to suppress collagen-induced platelet aggregation, but did not affect blood coagulation. In conclusion, XC386 was proved to be as effective as aspirin and indomethacin in preventing the death of acute pulmonary thromboembolism.
D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects*; D006400:Hematocrit; D006493:Heparin / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D051379:Mice; D010974:Platelet Aggregation / Q000187:drug effects*; D011720:Pyrazoles / Q000494:pharmacology*; D012772:Shock, Septic / Q000503:physiopathology; D013927:Thrombosis / Q000517:prevention & control*; D013997:Time Factors
D011720:Pyrazoles; C043588:XC 386; D006493:Heparin; D001241:Aspirin; D007213:Indomethacin